# US 2025/0375459 A1 · Methods for ameliorating cognitive impairment using bile acid derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375459 A1
- Document ID: US20250375459A1
- Status: Published application
- Kind: A1
- Application number: 18/878,533
- Filed: 2023-06-30
- Published: 2025-12-11
- Earliest claimed: 2022-07-01
- Applicants: Intercept Pharmaceuticals, Inc.
- Inventors: David E. JONES; Fiona OAKLEY
- Web page: https://patentgrep.com/patent/US20250375459A1

## CPC

- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure relates to methods of using bile acid derivatives for the treatment and/or prevention of cognitive disorders, diseases, or conditions.

## Claims

### Claim 1

A method of ameliorating, mitigating, treating, or preventing cognitive impairment in a subject, comprising administering to the subject at least one therapeutically effective amount of a compound of formula (I):
or a pharmaceutically acceptable salt, ester, solvate, or amino acid conjugate thereof, wherein:
R1 is H, OH, alkoxy, or oxo;
R2 is H, OH, halogen, or alkyl optionally substituted with one or more halogen or OH, or R2 and R3 taken together with the carbon atom to which they are attached form a carbonyl;
R3 is H, or R2 and R3 taken together with the carbon atom to which they are attached form a carbonyl;
R4 is H, halogen, alkyl optionally substituted with one or more halogen or OH, alkenyl, or alkynyl;
R5 and R6 are each independently H, OH, OSO3H, OCOCH3, OPO3H2, or halogen, or R5 and R6 taken together with the carbon atom to which they are attached form a carbonyl;
R7 is OH, OSO3H, SO3H, OSO2NH2, SO2NH2, OPO3H2, PO3H2, CO2H, C(O)NHOH, tetrazolyl, oxadiazolyl, thiadiazolyl, 5-oxo-1,2,4-oxadiazolyl, 5-oxo-1,2,4-thiadiazolyl, oxazolidine-dionyl, thiazolidine-dionyl, 3-hydroxyisoxazolyl, 3-hydroxyisothiazolyl, or 2,4-difluoro-3-hydroxyphenyl;
R8, R9, and R10 are each independently H, OH, halogen, or alkyl optionally substituted with one or more halogen or OH, or R8 and R9 taken together with the carbon atoms to which they are attached form a 3- to 6-membered carbocyclic or heterocyclic ring comprising 1 or 2 heteroatoms selected from N, O, and S, or R9 and R10 taken together with the carbon atoms to which they are attached form a 3- to 6-membered carbocyclic or heterocyclic ring comprising 1 or 2 heteroatoms selected from N, O, and S;
m is 0, 1, or 2;
n is 0 or 1; and
p is 0 or 1.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound of formula (I) is a compound of formula (A):
or pharmaceutically acceptable salt, ester, solvate, or amino acid conjugate thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the compound of formula (I) is a compound of formula (A).

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound of formula (I) is a compound of formula (B):
or pharmaceutically acceptable salt, ester, solvate, or amino acid conjugate thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein the compound of formula (I) is a compound of formula (B).

### Claim 6 (depends on 1)

The method of claim 1, wherein the compound of formula (I) is a compound of formula (C):
or pharmaceutically acceptable salt, ester, solvate, or amino acid conjugate thereof.

### Claim 7 (depends on 6)

The method of claim 6, wherein the compound of formula (I) is a compound of formula (C).

### Claim 8 (depends on 1)

The method of claim 1, wherein the compound of formula (I) is a compound of formula (D):
or pharmaceutically acceptable salt, ester, solvate, or amino acid conjugate thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the compound of formula (I) is a compound of formula (D).

### Claim 10 (depends on 1)

The method of claim 1, wherein the cognitive impairment is associated with a neurological disease.

### Claim 11 (depends on 10)

The method of claim 10, wherein the neurological disease is Parkinson's disease.

### Claim 12 (depends on 10)

The method of claim 10, wherein the neurological disease is Parkinson's disease dementia.

### Claim 13 (depends on 10)

The method of claim 10, wherein the neurological disease is mild cognitive impairment in Parkinson's disease dementia (PD-MCI).

### Claim 14 (depends on 1)

The method of claim 1, wherein the effective amount of the compound of formula (I) is between about 1 mg and about 50 mg.

### Claim 15 (depends on 14)

The method of claim 14, wherein the effective amount of the compound of formula (I) is between about 1 mg and about 25 mg.

### Claim 16 (depends on 14)

The method of claim 14, wherein the effective amount of the compound of formula (I) is about 25 mg.

### Claim 17 (depends on 1)

The method of claim 1, wherein the effective amount of the compound of formula (I) is administered about every day, about every two days, about every three days, or about every week.

### Claim 18 (depends on 17)

The method of claim 17, wherein the effective amount of the compound of formula (I) is administered daily.

### Claim 19

A method of reversing cellular senescence associated with Parkinson's Disease in the neurons of a subject, comprising administering to the subject at least one therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt, ester, solvate, or amino acid conjugate thereof, wherein:
R1 is H, OH, alkoxy, or oxo;
R2 is H, OH, halogen, or alkyl optionally substituted with one or more halogen or OH, or R2 and R3 taken together with the carbon atom to which they are attached form a carbonyl;
R3 is H, or R2 and R3 taken together with the carbon atom to which they are attached form a carbonyl;
R4 is H, halogen, alkyl optionally substituted with one or more halogen or OH, alkenyl, or alkynyl;
R5 and R6 are each independently H, OH, OSO3H, OCOCH3, OPO3H2, or halogen, or R5 and R6 taken together with the carbon atom to which they are attached form a carbonyl;
R7 is OH, OSO3H, SO3H, OSO2NH2, SO2NH2, OPO3H2, PO3H2, CO2H, C(O)NHOH, tetrazolyl, oxadiazolyl, thiadiazolyl, 5-oxo-1,2,4-oxadiazolyl, 5-oxo-1,2,4-thiadiazolyl, oxazolidine-dionyl, thiazolidine-dionyl, 3-hydroxyisoxazolyl, 3-hydroxyisothiazolyl, or 2,4-difluoro-3-hydroxyphenyl;
R8, R9, and R10 are each independently H, OH, halogen, or alkyl optionally substituted with one or more halogen or OH, or R8 and R9 taken together with the carbon atoms to which they are attached form a 3- to 6-membered carbocyclic or heterocyclic ring comprising 1 or 2 heteroatoms selected from N, O, and S, or R9 and R10 taken together with the carbon atoms to which they are attached form a 3- to 6-membered carbocyclic or heterocyclic ring comprising 1 or 2 heteroatoms selected from N, O, and S;
m is 0, 1, or 2;
n is 0 or 1; and
p is 0 or 1.

### Claim 20

A method of ameliorating, mitigating, treating, or preventing telomere dysfunction associated with Parkinson's Disease in the neurons of a subject, comprising administering to the subject at least one therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt, ester, solvate, or amino acid conjugate thereof, wherein:
R1 is H, OH, alkoxy, or oxo;
R2 is H, OH, halogen, or alkyl optionally substituted with one or more halogen or OH, or R2 and R3 taken together with the carbon atom to which they are attached form a carbonyl;
R3 is H, or R2 and R3 taken together with the carbon atom to which they are attached form a carbonyl;
R4 is H, halogen, alkyl optionally substituted with one or more halogen or OH, alkenyl, or alkynyl;
R5 and R6 are each independently H, OH, OSO3H, OCOCH3, OPO3H2, or halogen, or R5 and R6 taken together with the carbon atom to which they are attached form a carbonyl;
R7 is OH, OSO3H, SO3H, OSO2NH2, SO2NH2, OPO3H2, PO3H2, CO2H, C(O)NHOH, tetrazolyl, oxadiazolyl, thiadiazolyl, 5-oxo-1,2,4-oxadiazolyl, 5-oxo-1,2,4-thiadiazolyl, oxazolidine-dionyl, thiazolidine-dionyl, 3-hydroxyisoxazolyl, 3-hydroxyisothiazolyl, or 2,4-difluoro-3-hydroxyphenyl;
R8, R9, and R10 are each independently H, OH, halogen, or alkyl optionally substituted with one or more halogen or OH, or R8 and R9 taken together with the carbon atoms to which they are attached form a 3- to 6-membered carbocyclic or heterocyclic ring comprising 1 or 2 heteroatoms selected from N, O, and S, or R9 and R10 taken together with the carbon atoms to which they are attached form a 3- to 6-membered carbocyclic or heterocyclic ring comprising 1 or 2 heteroatoms selected from N, O, and S;
m is 0, 1, or 2;
n is 0 or 1; and
p is 0 or 1.

### Claim at position 21

21-23. (canceled)

### Claim 24

A kit for treating, ameliorating, or mitigating cognitive impairment in a subject, comprising at least one therapeutically effective amount of a compound of formula (I):
or a pharmaceutically acceptable salt, ester, solvate, or amino acid conjugate thereof, and instructions for use; wherein:
R1 is H, OH, alkoxy, or oxo;
R2 is H, OH, halogen, or alkyl optionally substituted with one or more halogen or OH, or R2 and R3 taken together with the carbon atom to which they are attached form a carbonyl;
R3 is H, or R2 and R3 taken together with the carbon atom to which they are attached form a carbonyl;
R4 is H, halogen, alkyl optionally substituted with one or more halogen or OH, alkenyl, or alkynyl;
R5 and R6 are each independently H, OH, OSO3H, OCOCH3, OPO3H2, or halogen, or R5 and R6 taken together with the carbon atom to which they are attached form a carbonyl;
R7 is OH, OSO3H, SO3H, OSO2NH2, SO2NH2, OPO3H2, PO3H2, CO2H, C(O)NHOH, tetrazolyl, oxadiazolyl, thiadiazolyl, 5-oxo-1,2,4-oxadiazolyl, 5-oxo-1,2,4-thiadiazolyl, oxazolidine-dionyl, thiazolidine-dionyl, 3-hydroxyisoxazolyl, 3-hydroxyisothiazolyl, or 2,4-difluoro-3-hydroxyphenyl;
R8, R9, and R10 are each independently H, OH, halogen, or alkyl optionally substituted with one or more halogen or OH, or R8 and R9 taken together with the carbon atoms to which they are attached form a 3- to 6-membered carbocyclic or heterocyclic ring comprising 1 or 2 heteroatoms selected from N, O, and S, or R9 and R10 taken together with the carbon atoms to which they are attached form a 3- to 6-membered carbocyclic or heterocyclic ring comprising 1 or 2 heteroatoms selected from N, O, and S;
m is 0, 1, or 2;
n is 0 or 1; and
p is 0 or 1.

### Claim 25

A method of treating, ameliorating or mitigating cognitive impairment in a subject comprising administering to the subject a pharmaceutical composition comprising at least one therapeutically effective amount of a compound of formula (I):
or a pharmaceutically acceptable salt, ester, solvate, or amino acid conjugate thereof, and at least one pharmaceutically acceptable excipient; wherein:
R1 is H, OH, alkoxy, or oxo;
R2 is H, OH, halogen, or alkyl optionally substituted with one or more halogen or OH, or R2 and R3 taken together with the carbon atom to which they are attached form a carbonyl;
R3 is H, or R2 and R3 taken together with the carbon atom to which they are attached form a carbonyl;
R4 is H, halogen, alkyl optionally substituted with one or more halogen or OH, alkenyl, or alkynyl;
R5 and R6 are each independently H, OH, OSO3H, OCOCH3, OPO3H2, or halogen, or R5 and R6 taken together with the carbon atom to which they are attached form a carbonyl;
R7 is OH, OSO3H, SO3H, OSO2NH2, SO2NH2, OPO3H2, PO3H2, CO2H, C(O)NHOH, tetrazolyl, oxadiazolyl, thiadiazolyl, 5-oxo-1,2,4-oxadiazolyl, 5-oxo-1,2,4-thiadiazolyl, oxazolidine-dionyl, thiazolidine-dionyl, 3-hydroxyisoxazolyl, 3-hydroxyisothiazolyl, or 2,4-difluoro-3-hydroxyphenyl;
R8, R9, and R10 are each independently H, OH, halogen, or alkyl optionally substituted with one or more halogen or OH, or R8 and R9 taken together with the carbon atoms to which they are attached form a 3- to 6-membered carbocyclic or heterocyclic ring comprising 1 or 2 heteroatoms selected from N, O, and S, or R9 and R10 taken together with the carbon atoms to which they are attached form a 3- to 6-membered carbocyclic or heterocyclic ring comprising 1 or 2 heteroatoms selected from N, O, and S;
m is 0, 1, or 2;
n is 0 or 1; and
p is 0 or 1.
